Literature DB >> 669848

Melphalan-induced chromosome damage in sensitive and resistant human melanoma cell lines.

P G Parsons, L Morrison.   

Abstract

Twelve consecutive treatments of a human melanoma cell line (MM253) with melphalan gave a subline (MM253-12M) which was five times more resistant to melphalan with respect to survival. In contrast to mustard-resistant rodent cells, the MM253-12M line had a higher stemline number than the parent line while growth rate and cell and colony morphology were unchanged. A further melphalan treatment following attempted mutagenesis with UV did not increase resistance. In a comparison of these two lines with two melanoma lines derived from other patients and the rat XC line, resistance was correlated with lower frequency of melphalan-induced chromosome aberrations, determined 48 h after a 4-h exposure to melphalan (3 microgram/ml). In the two cell lines studied, aberration-free metaphase cells from treated culture had fewer chromosomes than untreated cells. DNA synthesis studied in the 4- to 72-h period after treatment was inhibited to the same extent in MM253 and MM253-12M cells at 4 microgram/ml but to a greater extent in the sensitive line at 0.1-1.5 microgram/ml. During the first hour of treatment at 0.1-1.5 microgram/ml, DNA synthesis in MM253 appeared to be enhanced.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 669848     DOI: 10.1002/ijc.2910210407

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Persistence of chromosome rearrangements in peripheral lymphocytes from patients treated with melphalan for ovarian carcinoma.

Authors:  B Lambert; K Holmberg; N Einhorn
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

3.  Chemoreduction of Orbital Recurrence of Uveal Melanoma by Intra-Arterial Melphalan.

Authors:  Jasmine H Francis; Christopher A Barker; Vivian T Yin; Richard D Carvajal; Paul Chapman; David H Abramson; Y Pierre Gobin
Journal:  Ocul Oncol Pathol       Date:  2018-10-09

4.  Development of drug resistance in a murine mammary tumour.

Authors:  T J McMillan; T C Stephens; G G Steel
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

5.  In vivo characterization of a doxorubicin resistant B16 melanoma cell line.

Authors:  F Formelli; C Rossi; R Supino; G Parmiani
Journal:  Br J Cancer       Date:  1986-08       Impact factor: 7.640

6.  Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts.

Authors:  R Berman; G G Steel
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.